Literature DB >> 33611488

Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery.

Evangelos Liberopoulos.   

Abstract

Entities:  

Year:  2020        PMID： 33611488     DOI： 10.1177/2047487320926777

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN： 2047-4873            Impact factor:   7.804


× No keyword cloud information.
  3 in total

Review 1.  Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

Authors:  Maria Francesca Greco; Cesare R Sirtori; Alberto Corsini; Marat Ezhov; Tiziana Sampietro; Massimiliano Ruscica
Journal:  J Clin Med       Date:  2020-07-03       Impact factor: 4.964

2.  Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.

Authors:  Evangelia Dounousi; Constantinos Tellis; Paraskevi Pavlakou; Anila Duni; Vasillios Liakopoulos; Patrick B Mark; Aikaterini Papagianni; Alexandros D Tselepis
Journal:  Oxid Med Cell Longev       Date:  2021-07-20       Impact factor: 7.310

3.  Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.

Authors:  Christos V Rizos; Matilda Florentin; Ioannis Skoumas; Konstantinos Tziomalos; Loukianos Rallidis; Vasileios Kotsis; Vasileios Athyros; Emmanouil Skalidis; Genovefa Kolovou; Anastasia Garoufi; Eleni Bilianou; Iosif Koutagiar; Dimitrios Agapakis; Estela Kiouri; Christina Antza; Niki Katsiki; Evangelos Zacharis; Achilleas Attilakos; George Sfikas; Panagiotis Anagnostis; Demosthenes B Panagiotakos; Evangelos N Liberopoulos
Journal:  Lipids Health Dis       Date:  2020-05-28       Impact factor: 4.315
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.